A compound represented by general structure: wherein, - T is a water-soluble vitamin E derivative having a core chromanyl or chromanyl quinone framework and a carboxylic acid moiety substituted at the 2-position, wherein T is connected to nitrogen via the carboxylic acid moiety, as such forming an amide moiety, wherein T is represented by structure (Illa) or (IIIb): wherein each R 7 is methyl; - L is a linker between the amide nitrogen atom and the distal nitrogen atom comprising 1 to 10 optionally substituted backbone atoms selected from carbon, nitrogen and oxygen; - N* is represented by structure ( IIa) or ( IIb) - R 1 and R 2 are each independently selected from hydrogen, C 1 - C 6 alkyl or C 1 - C 6 alkenyl, or R 1 and R 2 are joined together and thus form a second linker between the amide nitrogen atom and the distal nitrogen atom, or R 1 is joined with a backbone atom of the linker L in a cyclic structure and/or R 2 is joined with a backbone atom of the linker L in a cyclic structure; - R 3 is selected from hydrogen, C 1 - C 6 alkyl or C 1 - C 6 alkenyl, wherein the alkyl or alkenyl moiety may be substituted with one or more halogen atoms, hydroxyl moieties or (halo)alkoxy moieties, or R 3 is absent when the distal nitrogen atom is part of an imine moiety; or optionally R 3 is joined with a backbone atom of the linker L in a cyclic structure; and - R 4 is selected from hydrogen or C 1 - C 6 alkyl, wherein the alkyl moiety may be substituted with one or more halogen atoms or (halo)alkoxy moieties; - X is a pharmaceutically acceptable anion, for use in a treatment for preventing or suppressing symptoms mediated by enhanced mPGES-1 expression or activity. - T is a water-soluble vitamin E derivative having a core chromanyl or chromanyl quinone framework and a carboxylic acid moiety substituted at the 2-position, wherein T is connected to nitrogen via the carboxylic acid moiety, as such forming an amide moiety, wherein T is represented by structure (Illa) or (IIIb): wherein each R 7 is methyl; - L is a linker between the amide nitrogen atom and the distal nitrogen atom comprising 1 to 10 optionally substituted backbone atoms selected from carbon, nitrogen and oxygen; - N* is represented by structure ( IIa) or ( IIb) - R 1 and R 2 are each independently selected from hydrogen, C 1 - C 6 alkyl or C 1 - C 6 alkenyl, or R 1 and R 2 are joined together and thus form a second linker between the amide nitrogen atom and the distal nitrogen atom, or R 1 is joined with a backbone atom of the linker L in a cyclic structure and/or R 2 is joined with a backbone atom of the linker L in a cyclic structure; - R 3 is selected from hydrogen, C 1 - C 6 alkyl or C 1 - C 6 alkenyl, wherein the alkyl or alkenyl moiety may be substituted with one or more halogen atoms, hydroxyl moieties or (halo)alkoxy moieties, or R 3 is absent when the distal nitrogen atom is part of an imine moiety; or optionally R 3 is joined with a backbone atom of the linker L in a cyclic structure; and - R 4 is selected from hydrogen or C 1 - C 6 alkyl, wherein the alkyl moiety may be substituted with one or more halogen atoms or (halo)alkoxy moieties; - X is a pharmaceutically acceptable anion,